 | January 1, 2012
By:William Looney
The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
 |
 | December 1, 2011
By:Ben Comer
It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
|
 | December 1, 2011
By:George Baeder
Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?
|
October 1, 2011
Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence
|
October 1, 2011
Y.K. Hamied, PhD, Chairman, Cipla
|
September 1, 2011
By:Dr. Jill Conner
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
|
August 1, 2011
By:Reflector
HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.
|
 | August 1, 2011
By:Ben Comer
When it comes to the emerging markets, executing a few key elements of success are more important than ever.
|
July 1, 2011
By:Reflector
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
